What Changes When Iomeprol Is Diluted for Enteric CT Marking?

For oral and enteric CT marking, iomeprol is used as an intraluminal positive contrast agent rather than a systemic diagnostic. Systemic absorption from the intact gastrointestinal tract is negligible, which supports the use of iomeprol as a water-soluble iodine signal when barium is not preferred. Industrial oral liquid manufacture begins with dissolution of the API in purified water, followed by pH adjustment and dilution to a protocol-specific iodine concentration. Unlike injectable manufacture, terminal sterilization is not universal for oral liquids; hot filling or chemical preservation may be omitted only if the product is filled under controlled low-bioburden conditions. The critical physical property is osmolality, because a concentrated oral dose can provoke osmotic diarrhea and fluid shifts. Dilution ratios are therefore managed through gravimetric batching rather than volumetric addition to maintain batch-to-batch consistency. Packaging in amber high-density polyethylene or glass bottles with child-resistant closures protects the solution from light and limits iodine liberation during shelf storage. Release testing for an oral iomeprol solution includes assay by HPLC, pH, density, microbial enumeration per USP <61> and USP <62>, and absence of free iodine. The oral route is not a substitute for intravascular injection when systemic vascular enhancement is required; the clinical protocol defines whether the patient receives oral iomeprol alone or oral followed by intravenous contrast. Published dilution protocols vary across institutions, and no single standardized concentration exists for all CT enterography workflows.

On a large-volume oral liquid line, the main bottleneck is foaming during high-shear mixing of a high-density solution. Vacuum deaeration or nitrogen counterflow is applied before filling to prevent cavitation in rotary piston fillers. Fill volume tolerances for oral liquids are wider than for injectables but must still comply with the metered dose accuracy requirements of the applicable national pharmacopoeia. Transfer lines are constructed from 316L stainless steel or high-purity polymer to avoid metal-catalysed iodide oxidation.

When Solid Oral Dose Forms Are Considered for GI Transit Imaging

When tablets or capsules are evaluated for GI transit imaging, iomeprol presents a high-dose, high-solubility formulation challenge. A single tablet containing 300 mg to 600 mg of iodine would be possible from a compression standpoint, but full CT bowel marking would require multiple units and delayed disintegration in the distal ileum. Wet granulation is preferred over direct compression because iomeprol powder, after storage, tends to form agglomerates that segregate in low-shear feeders. The granulation end-point is determined by impeller power consumption and torque rather than fixed time. After fluid-bed drying, granules are milled through a 1.0 mm conical mill screen and blended with crospovidone and sodium stearyl fumarate. Tablet hardness is maintained at 80 N to 120 N to ensure fracture resistance without slowing disintegration. Capsule filling is feasible with size 00 or size 000 hard gelatin or hypromellose capsules, but the mass of API and diluent may exceed 800 mg per capsule, which reduces patient acceptability. Dissolution testing in USP <711> apparatus II at 75 rpm in water is expected to show immediate release from an immediate-release matrix; no enteric coating is applied because the API must remain intraluminal. Content uniformity follows USP <905> or Ph. Eur. 2.9.40. Stability storage under 25°C/60% RH and accelerated conditions 40°C/75% RH follows ICH Q1A(R2). No approved commercial tablet or capsule product exists for iomeprol in major markets; published data for this specific configuration is limited, and formulation work remains investigational rather than compendial.

Intra-Arterial and Body Cavity Administration: Viscosity, Injection Rate, and Local Tolerance

Across intra-arterial and body-cavity procedures, iomeprol solutions are selected where low-osmolality iodine signal is required. The API is formulated as a clear, colourless to pale yellow solution that is injected through catheters with internal diameters as small as 0.5 mm (4 Fr to 5 Fr) during angiography. The viscosity of iomeprol solutions at 37°C is lower than that of ionic dimeric contrast agents, which allows higher flow rates through narrow catheters, but the actual pressure limit is also defined by catheter burst rating and the injection pump pressure cutoff. For hysterosalpingography, intra-articular injection, and retrograde urograms, the volume and iodine concentration are reduced relative to intravenous CT use; concentrations of 150 mg iodine/mL to 300 mg iodine/mL are typically selected to balance local radiopacity with tissue tolerance. The injection is performed under fluoroscopic control, and the solution should be at body temperature before administration to reduce viscosity and patient discomfort. Body-cavity sites do not require the same sterile fill volume as a 100 mL intravenous bottle, but the product must meet the same particulate, sterility, and endotoxin standards as an injectable. The product is supplied in single-use containers, and any unused portion is discarded because the preservative-free formulation does not support multi-dose use. If the solution is pre-warmed, the warming cabinet is set to 37°C and the product is protected from light until the moment of injection. Local tolerance is influenced by pH and iodine concentration; formulations are buffered to physiological pH to reduce injection-site pain and tissue irritation.

Automated Hospital Pharmacy Compounding of Patient-Specific Oral and Injectable Iomeprol Dosages

Within hospital pharmacy central admixture units, iomeprol is processed in sterile and nonsterile compounding modes. Injectable aliquoting is performed inside ISO 5 laminar airflow or compounding aseptic isolators in accordance with USP <797>. The stock solution is drawn from single-use vials using closed-system transfer devices to reduce needle-stick and microbial ingress. For oral use, the pharmacist dilutes the injectable or API-based oral solution to the protocol-specific concentration using pharmacy-grade water or a low-osmolality vehicle; beyond-use dating is assigned based on USP <795> and container closure. Automated compounders with gravimetric verification are calibrated for the density of iomeprol solutions, which is above that of water. Batch records record the lot number of the API or stock solution, the diluent volume, the final iodine concentration, and the storage temperature. The compounded oral dose is labelled with a light-protective cover and stored in a refrigerator at 2°C to 8°C unless stability data supports longer room-temperature storage. For injectable admixtures, the final container is inspected for visible particles and administered through a low-sorption administration set. This practice transfers the burden of concentration accuracy from the original manufacturer to the hospital pharmacy, so gravimetric rather than volumetric verification is preferred.

In injectable diagnostic manufacturing, iomeprol pharma grade API is handled as an injectable-grade bulk drug substance with an iodine content of approximately 49.0% w/w. The molecular weight of the non-ionic tri-iodinated monomer is 777.09 g/mol. When a high-speed aseptic fill line is set for a final solution concentration of 300 mg iodine/mL, the required API concentration is 612.2 mg/mL; for 350 mg iodine/mL the target is 714.3 mg/mL; for 400 mg iodine/mL the target is 816.3 mg/mL. Dissolution is carried out in Water for Injection at 20°C to 25°C in a closed stainless-steel mixing vessel with bottom-mounted agitation. The solution is blanketed with pharmaceutical-grade nitrogen during compounding to reduce oxidative discoloration and free iodide release. The pH is adjusted to 6.5–7.5 using dilute hydrochloric acid or tromethamine, the latter serving as a low-concentration buffer in several marketed injectable formulations. The liquid is passed through a 0.22 µm sterilizing-grade polyethersulfone or polyvinylidene fluoride membrane filter before aseptic filling into Type I borosilicate glass vials. Headspace nitrogen flushing and halogenated butyl rubber closures are used to limit oxygen exposure. Where terminal sterilization is validated, a saturated steam cycle at 121°C for 15 minutes is applied; otherwise the line is operated entirely under aseptic conditions. Filled units undergo 100% visible particle inspection under dark-field illumination aligned with USP <790>, and batch release includes subvisible particle counts per USP <788> and bacterial endotoxin testing per USP <85>.

The principal manufacturing conflict on a high-speed line is the high fill volume combined with the viscosity of the 400 mg iodine/mL grade. Fill pumps are calibrated with volume displacement rather than time-pressure systems to avoid short-shot vials. In-process fill volume control uses start/middle/end sampling and a tightened acceptance range of ±1.5% of target volume. Stopper insertion depth is inspected after capping to avoid microleakage during terminal steam sterilization. The API lot itself is controlled for bioburden and endotoxin before dissolution because incoming parenteral-grade drug substance may not be sterile; acceptance limits are derived from sterilizing filtration validation and final-release safety data.

Before tableting or capsule filling, iomeprol may be converted into a granule intermediate for reconstitutable oral contrast sachets. The process begins with roller compaction or fluid-bed spray granulation using an aqueous binder solution of hypromellose or povidone; the resulting granules are sieved to a target size range of 200 µm to 800 µm and filled into single-dose sachets or multi-dose containers. Granule intermediate tests include loss on drying, bulk density, tapped density, particle size distribution by analytical sieving per USP <786>, and HPLC assay. Moisture protection is critical because even small amounts of free water can initiate surface dissolution and caking, which slows reconstitution in water. Sachet filling is performed on a vertical form-fill-seal machine with a nitrogen flush; fill weight variation is monitored every 15 minutes using automatic checkweighing. Reconstitution time is validated, with a typical target of less than 2 minutes for a 10 g granule dose dispersed in 200 mL of water at 20°C, although the exact acceptance limit is product-specific. The oral solution produced from granules is intended for positive GI marking in CT or fluoroscopy; systemic absorption remains negligible. The main equipment bottleneck is electrostatic charging of dry granules during low-humidity transfer, which causes weight variation and dust formation. To avoid this, transfer lines are electrically grounded and room humidity is maintained above 30% RH but below 60% RH to balance flow and moisture pickup.